ABL Diagnostics (FRA:9BK0) Research & Development: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:9BK0 ABL Diagnostics FRA:9BK0
50 GF Score
Price €2.76
GF Value €7.34
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Research & Development?

ABL Diagnostics FRA:9BK0 50 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:9BK0 with a GF Score™ of 50/100 and a GF Value™ of €7.34 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ABL Diagnostics's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

ABL Diagnostics  (FRA:9BK0) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ABL Diagnostics Research & Development Related Terms

ABL Diagnostics Research & Development Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics Research & Development Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9BK0
50GF Score
ABL Diagnostics FRA:9BK0
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
ABL Diagnostics (FRA:9BK0) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on ABL Diagnostics and its competitors.
Is ABL Diagnostics' Research & Development too high?
ABL Diagnostics' current Research & Development is €0.00 Mil. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Research & Development compare to VEEV and BTSG?
ABL Diagnostics' Research & Development of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (FRA:9BK0) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.34, compared to a current price of €2.76 — trading 62.4% below its estimated fair value. The current Research & Development is €0.00 Mil. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ABL Diagnostics (FRA:9BK0), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (FRA:9BK0) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.76 is trading 62.4% below its estimated GF Value™ of €7.34. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for FRA:9BK0:

  • Research & Development: €0.00 Mil
  • GF Value™: €7.34 vs. price of €2.76 (62.4% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the FRA:9BK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges ABLD:France
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score

Get the complete analysis for FRA:9BK0

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.76
Price
€7.34
GF Value